Moderna's share price exploded between 160% and 177% in a single session — the exact figure varied across intraday reports — after the company announced positive results from a late-stage clinical trial for its personalised melanoma treatment, according to Business Insider Africa. The move marks one of the most dramatic single-day recoveries for a large-cap biotech in recent memory.
The drug at the centre of the surge is a messenger RNA-based individualised neoantigen therapy — the same mRNA platform Moderna used to develop its COVID-19 vaccine. The melanoma treatment is developed in partnership with Merck and works by training the immune system to target mutations unique to each patient's tumour. A late-stage trial, the most advanced phase before regulatory submission, showed the combination of Moderna's vaccine with Merck's blockbuster immunotherapy Keytruda produced statistically meaningful results.
The timing matters. Moderna had spent roughly two years in freefall after COVID-19 vaccine demand collapsed. Revenue that peaked above $18 billion in 2022 cratered as booster uptake slowed and governments drew down stockpiles. The company was burning cash, cutting its workforce, and under pressure to prove its mRNA platform could generate a second commercial act beyond COVID. This trial result is the first hard late-stage evidence that it can.
For African markets, the development carries layered significance. Melanoma is typically framed as a disease of lighter-skinned populations, but the data on Africa is more complicated: the disease is frequently diagnosed late on the continent, particularly acral and mucosal subtypes that affect people regardless of skin tone, and late-stage diagnoses carry sharply worse survival outcomes. A commercially viable personalised cancer vaccine would, in principle, eventually reach African patients — though access timelines and pricing remain the critical unknowns.
More immediately relevant to African investors and fund managers tracking global biotech is what this moment signals about mRNA as an asset class. The platform was stress-tested at industrial scale during COVID and is now moving into oncology, influenza, cardiovascular disease, and rare conditions. Moderna's pipeline includes candidates across all four areas. A single positive readout has restored, at least temporarily, the market's willingness to price that pipeline at a premium rather than a discount.
Merck's role should not be understated. Keytruda — pembrolizumab — is already the world's best-selling cancer drug, generating roughly $25 billion in annual revenue. Pairing it with a personalised mRNA vaccine gives Merck a differentiated combination that could extend Keytruda's commercial life well beyond the patent cliff it faces later this decade. For Moderna, a successful co-commercialisation deal with a partner of Merck's scale would provide the distribution muscle and revenue share a company of its current size badly needs.
The stock surge also resets the conversation around Moderna's cash runway. The company had been spending heavily on R&D while revenues shrank, raising questions about how long it could fund its pipeline without dilutive capital raises. A market capitalisation jump of this magnitude — even if it partly retraces — improves the terms on which Moderna could raise equity or debt if needed, and may attract partnership interest from larger pharmaceutical groups looking to acquire or license mRNA oncology assets.
African institutional investors with exposure to global health equities through ETFs or direct holdings will have felt this move in their portfolios. South Africa's Government Employees Pension Fund, one of the largest on the continent, holds international equities as part of its asset allocation; so do several Nigerian and Kenyan pension funds seeking diversification beyond local markets. A 160%-plus move in a single session in a position they hold is a meaningful event regardless of portfolio weight.
Why it matters: Moderna's melanoma trial result is not just a biotech headline — it is the first credible proof that mRNA can anchor a second commercial franchise, one that could eventually reshape how cancer is treated globally, including in African markets where late-stage diagnosis remains the norm. The 160-177% share price move reflects the market's view that the platform's value had been severely mispriced; whether that repricing holds will depend on regulatory submissions and, ultimately, the price at which any approved therapy reaches patients in lower-income markets.